Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 25;10(7):1190.
doi: 10.3390/healthcare10071190.

Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review

Andrea Marani  1 , Giulio Rizzetto  1 , Giulia Radi  1 , Elisa Molinelli  1 , Irene Capodaglio  2 , Annamaria Offidani  1 , Oriana Simonetti  1
Affiliations

Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review

Andrea Marani et al. Healthcare (Basel). .

Abstract

Psoriasis vulgaris is a common inflammatory, immune mediated, chronic recurrent dermatosis. Psoriasis is also a systemic inflammatory disease, associated with numerous comorbidities, particularly metabolic ones. Here, we summarize and discuss, in a narrative review, the current knowledge about the metabolic comorbidities in psoriatic children. Obesity, insulin resistance, diabetes, cardiovascular disease, and dyslipidemia are identified as the main comorbidities in psoriatic children. In conclusion, dermatologists should be aware of the metabolic comorbidities in children with psoriasis, modulating the therapeutic approach according to the patient's clinical condition.

Keywords: children; comorbidities; diabetes; lipids; lipoprotein; metabolism; obesity; peroxidation; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Eichenfield L.F., Paller A.S., Tom W.L., Sugarman J., Hebert A.A., Friedlander S.F., Siegfried E., Silverberg N., Cordoro K.M. Pediatric psoriasis: Evolving perspectives. Pediatr. Dermatol. 2018;35:170–181. doi: 10.1111/pde.13382. - DOI - PubMed
    1. Simonetti O., Lucarini G., Campanati A., Goteri G., Zizzi A., Marconi B., Ganzetti G., Minardi D., Di Primio R., Offidani A. VEGF, survivin and NOS overexpression in psoriatic skin: Critical role of nitric oxide synthases. J. Dermatol. Sci. 2009;54:205–208. doi: 10.1016/j.jdermsci.2008.12.012. - DOI - PubMed
    1. Kittler N.W., Cordoro K.M. Pediatric Psoriasis Comorbidities. Ski. Ther. Lett. 2020;25:1–6. - PubMed
    1. Osier E., Wang A.S., Tollefson M.M., Cordoro K.M., Daniels S.R., Eichenfield A., Gelfand J.M., Gottlieb A.B., Kimball A.B., Lebwohl M., et al. Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol. 2017;153:698–704. doi: 10.1001/jamadermatol.2017.0499. - DOI - PMC - PubMed
    1. Augustin M., Glaeske G., Radtke M.A., Christophers E., Reich K., Schafer I. Epidemiology and comorbidity of psoriasis in children. Br. J. Dermatol. 2010;162:633–636. doi: 10.1111/j.1365-2133.2009.09593.x. - DOI - PubMed

LinkOut - more resources